On August 27, Novo Nordisk China announced that it has officially accepted its marketing application for oral weight loss version of simeglutide tablets for long-term weight management. The registration application is based on the OASIS clinical research project. This global phase 3 clinical program includes 4 trials and included 1,300 adult patients with obesity or overweight from various countries and regions around the world with at least one related complication. Eli Lilly has previously submitted a marketing application for orforglipron for the treatment of type 2 diabetes and adult weight management, which is expected to be officially approved this year. At that time, the competition between the two diet drug giants in China will enter the oral administration field.

On August 27, Novo Nordisk China announced that it has officially accepted its marketing application for oral weight loss version of simeglutide tablets for long-term weight management. The registration application is based on the OASIS clinical research project. This global phase 3 clinical program includes 4 trials and included 1,300 adult patients with obesity or overweight from various countries and regions around the world with at least one related complication. Eli Lilly has previously submitted a marketing application for orforglipron for the treatment of type 2 diabetes and adult weight management, which is expected to be officially approved this year. At that time, the competition between the two diet drug giants in China will enter the oral administration field.